Tesamorelin boosts a key growth hormone-related protein in HIV patients without affecting their blood sugar levels.
Scientific Claim
Tesamorelin increases insulin-like growth factor-1 levels (P < 0.001) without altering glucose parameters in HIV-infected patients on antiretroviral therapy.
Original Statement
“Insulin-like growth factor-1 increased (P < 0.001), but no change in glucose parameters was observed.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The study is a randomized controlled trial with a control group, which allows for causal inference. The verbs 'increases' and 'without altering' are appropriate for this design.
Evidence from Studies
Supporting (1)
The study found that tesamorelin raised a growth-related hormone (IGF-I) in HIV patients without affecting their blood sugar, which is exactly what the claim says.